<DOC>
	<DOCNO>NCT00237614</DOCNO>
	<brief_summary>Patients acute myocardial infarction undergo primary angioplasty high risk renal injury due toxic effect contrast agent . Patients develop renal dysfunction primary angioplasty bad outcome . To investigate role antioxidant N-acetylcysteine ( NAC ) prevent renal injury angioplasty , randomize 352 consecutive patient undergo primary angioplasty three group : first group receive NAC standard dose ( NAC group , 600 mg i.v . bolus primary angioplasty , follow oral 600 mg twice daily follow 48 hour ; n=115 ) , second group receive NAC double dose ( DD-NAC group ; 1,200 mg i.v . bolus oral 1,200 mg twice daily 48 hour ; n=118 ) , last group receive placebo ( control ; n=119 ) .</brief_summary>
	<brief_title>Contrast Nephropathy Prevention With N-Acetylcysteine Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Consecutive patient admit Coronary Care Unit STsegment elevation acute myocardial infarction undergo primary angioplasty . Patients include present within 12 hour ( 18 hour acute myocardial infarction complicate cardiogenic shock ) onset symptom . Patients chronic peritoneal hemodialytic treatment know allergy Nacetylcysteine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>Contrast-induced nephropathy</keyword>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Primary coronary angioplasty</keyword>
</DOC>